A case of COVID-19-associated C-ANCA vasculitis, was successfully treated with rituximab therapy
Michael Filoramo1, Renish Contractor1, Deepak Chandramohan2
1FSU College of Medicine Daytona Beach Florida USA.
Abstract:
Both C-anti-neutrophil cytoplasmic antibody (ANCA) and P-ANCA vasculitis were reported to be associated with COVID-19 infection. The ideal management of COVID-19-associated ANCA vasculitis is unclear, as the experiences were limited to case reports. We presented a case of COVID-19-associated C-ANCA vasculitis, successfully treated with steroids and rituximab therapy without any significant adverse reactions.
More Related Videos
04:50Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain
Published on: May 16, 2025
07:25In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
Published on: May 4, 2017
Related Concept Videos
Tumor Immunotherapy
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
